Dr. Lyndsay J. Willmott, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 180
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: State University of New York at Buffalo School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
AZ license 46677 -
Obstetrics & Gynecology Physician
AZ license 46677
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
- Banner - University Medical Center Phoenix Phoenix, AZ
- Honorhealth Scottsdale Osborn Medical Center Scottsdale, AZ
- Verde Valley Medical Center Cottonwood, AZ
Medical groups
- Honorhealth Ambulatory (630 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 180
- Services billed
- 424
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 91 | 68 |
| Established patient office or other outpatient visit, 40-54 minutes | 85 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 80 | 60 |
| New patient office or other outpatient visit, 60-74 minutes | 37 | 37 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Odt (ondansetron) Other prescribers in Phoenix, AZ | 50 |
| Prochlorperazine Maleate Other prescribers in Phoenix, AZ | 49 |
| Dexamethasone Other prescribers in Phoenix, AZ | 40 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Phoenix, AZ | 25 |
| Estradiol Other prescribers in Phoenix, AZ | 15 |
| Gabapentin Other prescribers in Phoenix, AZ | 15 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Phoenix, AZ | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 102 payments worth $64,899 in total to this clinician.
| GlaxoSmithKline, LLC. | $20,366 |
|---|---|
| Merck Sharp & Dohme LLC | $13,773 |
| AbbVie Inc. | $13,138 |
| AstraZeneca Pharmaceuticals LP | $6,915 |
| Genmab U.S., Inc. | $4,985 |
| Daiichi Sankyo Inc. | $2,823 |
| Pfizer Inc. | $2,182 |
| Eisai Inc. | $110 |
| Compensation for services other than consulting (speaking, faculty) | $37,786 |
|---|---|
| Consulting Fee | $20,277 |
| Travel and Lodging | $4,319 |
| Food and Beverage | $2,517 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 11, 2025 | Consulting Fee LYNPARZA · Oncology | $6,700 |
| GlaxoSmithKline, LLC. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,800 |
| Merck Sharp & Dohme LLC May 2, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC May 30, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| AbbVie Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $4,725 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $4,350 |
| Genmab U.S., Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Tivdak · Oncology | $3,275 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $3,038 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $2,900 |
| AbbVie Inc. Nov 10, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,700 |
All 30 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee | $1,166 |
| GlaxoSmithKline, LLC. Dec 16, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Green Valley, AZ · in-kind | $100 |
| AstraZeneca Pharmaceuticals LP Dec 11, 2025 | Consulting Fee LYNPARZA · Oncology | $6,700 |
| Pfizer Inc. Dec 9, 2025 | Consulting Fee TIVDAK · ONCOLOGY | $1,440 |
| Pfizer Inc. Dec 9, 2025 | Consulting Fee TIVDAK · ONCOLOGY | $720 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $4,350 |
| AbbVie Inc. Nov 10, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,700 |
| GlaxoSmithKline, LLC. Nov 4, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Tucson, AZ · in-kind | $1,133 |
| GlaxoSmithKline, LLC. Oct 10, 2025 | Consulting Fee ZEJULA · ONCOLOGY | $2,175 |
| GlaxoSmithKline, LLC. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) ZEJULA · ONCOLOGY | $1,089 |
| AbbVie Inc. Sep 12, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DENVER, CO · in-kind | $358 |
| AbbVie Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $4,725 |
| AbbVie Inc. Aug 27, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to TUCSON, AZ · in-kind | $830 |
| Genmab U.S., Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Tivdak · Oncology | $3,275 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $1,458 |
| Merck Sharp & Dohme LLC Jul 21, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $915 |
| GlaxoSmithKline, LLC. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,800 |
| Merck Sharp & Dohme LLC May 30, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC May 30, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Honolulu, HI | $150 |
| Merck Sharp & Dohme LLC May 2, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $3,038 |
| Merck Sharp & Dohme LLC May 2, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM | $150 |
| Merck Sharp & Dohme LLC Apr 22, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM · in-kind | $500 |
| Merck Sharp & Dohme LLC Apr 22, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM · in-kind | $239 |
| AbbVie Inc. Apr 11, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind | $555 |
| AbbVie Inc. Apr 11, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind | $304 |
| GlaxoSmithKline, LLC. Mar 27, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $1,450 |
| GlaxoSmithKline, LLC. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $1,089 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee | $1,554 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $1,913,828 in research payments for these studies, mostly to the institutions running them.
- Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Genmab U.S., Inc. - A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have…
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT…
Merck Sharp & Dohme LLC - A phase third,randomized,double blind,placebo controlled,multi centre,global study of volrustomig in women with high risk locally advanced cervical cancer who have not progressed following platinum based,concurrent ch…
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After …
Merck Sharp & Dohme LLC - A phase iii multicenter randomized placebo controlled study of atezolizumab versus placebo in com
Genentech, Inc. - A randomized, double-blind, phase 3 comparison of platinum-based thera
GlaxoSmithKline, LLC. - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serou…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.